Mr. Mariusz Olejniczak reports

On Oct. 16, 2023, the district court of Warsaw, Poland, registered an increase in the share capital of WPD Pharmaceuticals Inc.'s Polish subsidiary, WPD Pharmaceuticals Sp zoo, in connection with the investment by ACRX Investments Ltd. in shares of WPD Poland pursuant to an investment agreement announced by the company on Sept. 1, 2023. Refer to WPD's press releases of Sept. 1 and Sept. 8, 2023, filed on SEDAR+ for more information regarding ACRX and the investment agreement.

On Oct. 25, 2023, WPD Poland's equity capital was increased by the issuance to ACRX of a total 13,524 shares at a value of 50 Polish zloty each for total consideration paid to WPD Poland of 1,126,950 Polish zloty ($368,626). These funds will be allocated especially for further financing of the Berubicin project and preparation of assumptions for the project WPD401 (interceptor) project, which WPD Poland plans to implement in co-operation with Wake Forest University. WPD Poland is conducting projects for the oncological development of a chemical drug for chemotherapy in the treatment of glioblastoma (GBM).

We seek Safe Harbor.